Table 1 Clinical characteristics of patients with CWS
From: Capsular warning syndrome: clinical analysis and treatment
N = 72 | |
|---|---|
Age, year (Mean ± SD); | 66.28 ± 7.90; |
NIHSS score, median (IQR) | 8 (5–9) |
Systolic pressure, mmHg (Mean ± SD) | 167.75 ± 22.76 |
Glucose, mmol/l (Mean ± SD) | 6.58 ± 1.81 |
Mean number of episodes, n (Mean ± SD) | 5.31 ± 2.22 |
Mean Duration, min (Mean ± SD) | 24.11 ± 11.21 |
ABCD2 score, median (IQR) | 5 (4–5) |
Men, n (%) | 42 (58.33) |
BMI ≥ 24 kg/m, n (%) | 16 (22.22) |
Hypertension, n (%) | 52 (72.22) |
Current Smoking, n (%) | 26 (36.11) |
Current alcohol drinking, n (%) | 24 (33.33) |
Diabetes, n (%) | 27 (37.50) |
Hyperlipidemia, n (%) | 47 (65.28) |
Family history of stroke, n (%) | 16 (22.22) |
Medications use | |
Antiplatelet, n (%) | 22 (30.56) |
Antihypertensive, n (%) | 31 (43.06) |
Lipid-lowering medications, n (%) | 36 (50.00) |
Lacunar syndrome | |
Pure motor syndrome, n (%) | 32 (44.44) |
Pure sensory syndrome, n (%) | 12 (16.67) |
Sensory motor syndrome, n (%) | 24 (33.33) |
Ataxic hemiparesis, n (%) | 4 (5.56) |
Infarct location (58) | |
Internal capsule, n (%) | 41 (70.69) |
Pons, n (%) | 5 (8.62) |
Striatum, n (%) | 2 (3.44) |
Thalamus, n (%) | 7 (12.07) |
Midbrain, n (%) | 3 (5.17) |
Treatment | |
Rt-PA, n (%) | 27 (37.50) |
Double Antiplatelet, n (%) | 30 (41.67) |
Single Antiplatelet (15) | |
Aspirin, n (%) | 12 (16.67) |
Clopidogrel, n (%) | 3 (4.17) |